28 January, 2022
Cancer is a very heterogeneous disease and that is why research is being carried out to develop treatments that are adapted to the characteristics of each subtype. But then there is the challenge of identifying which patients benefit most from each treatment. With this in mind, HER2DX has been created, a genomic test that predicts survival and the possibility of responding to treatment in HER2-positive breast cancer patients in their earliest stages. This tool is the first genomic test created worldwide for this disease and researchers from the Clínic – IDIBAPS – UB, the Vall d’Hebron Instituto de Oncología, the Università di Padova (Italia) and REVEAL GENOMICS.